A citation-based method for searching scientific literature

G Bonadonna, P Valagussa, C Brambilla, L Ferrari. Lancet 1993
Times Cited: 31

List of co-cited articles
131 articles co-cited >1

Times Cited
  Times     Co-cited

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
G Bonadonna, U Veronesi, C Brambilla, L Ferrari, A Luini, M Greco, C Bartoli, G Coopmans de Yoldi, R Zucali, F Rilke. J Natl Cancer Inst 1990

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.
I E Smith, G Walsh, A Jones, J Prendiville, S Johnston, B Gusterson, F Ramage, H Robertshaw, N Sacks, S Ebbs. J Clin Oncol 1995

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
T J Powles, T F Hickish, A Makris, S E Ashley, M E O'Brien, V A Tidy, S Casey, A G Nash, N Sacks, D Cosgrove. J Clin Oncol 1995

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.
G N Hortobagyi, F C Ames, A U Buzdar, S W Kau, M D McNeese, D Paulus, V Hug, F A Holmes, M M Romsdahl, G Fraschini. Cancer 1988

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, E R Fisher, D L Wickerham, M Begovic, A DeCillis, A Robidoux,[...]. J Clin Oncol 1998

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, R G Margolese, A B Cruz, E R Fisher, D L Wickerham, N Wolmark,[...]. J Clin Oncol 1997

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.
S M Scholl, A Fourquet, B Asselain, J Y Pierga, J R Vilcoq, J C Durand, T Dorval, T Palangié, M Jouve, P Beuzeboc. Eur J Cancer 1994

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014

Pathological assessment of response to induction chemotherapy in breast cancer.
L D Feldman, G N Hortobagyi, A U Buzdar, F C Ames, G R Blumenschein. Cancer Res 1986

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
A Makris, T J Powles, M Dowsett, C K Osborne, P A Trott, I N Fernando, S E Ashley, M G Ormerod, J C Titley, R K Gregory,[...]. Clin Cancer Res 1997

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.
D A Cameron, E D Anderson, P Levack, R A Hawkins, T J Anderson, R C Leonard, A P Forrest, U Chetty. Br J Cancer 1997

Primary systemic therapy for operable breast cancer.
E D Anderson, A P Forrest, R A Hawkins, T J Anderson, R C Leonard, U Chetty. Br J Cancer 1991

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.
Manfred Kaufmann, Gunter von Minckwitz, Roy Smith, Vicente Valero, Luca Gianni, Wolfgang Eiermann, Anthony Howell, Serban Dan Costa, Philippe Beuzeboc, Michael Untch,[...]. J Clin Oncol 2003

Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer.
C Jacquillat, M Weil, F Baillet, C Borel, G Auclerc, M A de Maublanc, M Housset, G Forget, L Thill, C Soubrane. Cancer 1990

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
H B Muss, A D Thor, D A Berry, T Kute, E T Liu, F Koerner, C T Cirrincione, D R Budman, W C Wood, M Barcos. N Engl J Med 1994

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
P Ellis, I Smith, S Ashley, G Walsh, S Ebbs, M Baum, N Sacks, J McKinna. J Clin Oncol 1998

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
G Bonadonna, P Valagussa, C Brambilla, L Ferrari, A Moliterni, M Terenziani, M Zambetti. J Clin Oncol 1998

Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.
M De Lena, R Zucali, G Viganotti, P Valagussa, G Bonadonna. Cancer Chemother Pharmacol 1978

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
J Chang, T J Powles, D C Allred, S E Ashley, G M Clark, A Makris, L Assersohn, R K Gregory, C K Osborne, M Dowsett. J Clin Oncol 1999

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis. J Natl Cancer Inst 2005

Changes in biological markers after primary chemotherapy for breast cancers.
M G Daidone, R Silvestrini, A Luisi, M Mastore, E Benini, S Veneroni, C Brambilla, L Ferrari, M Greco, S Andreola. Int J Cancer 1995

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
B A Gusterson, R D Gelber, A Goldhirsch, K N Price, J Säve-Söderborgh, R Anbazhagan, J Styles, C M Rudenstam, R Golouh, R Reed. J Clin Oncol 1992

Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma.
P Verrelle, F Meissonnier, Y Fonck, V Feillel, C Dionet, F Kwiatkowski, R Plagne, J Chassagne. J Natl Cancer Inst 1991

Neoadjuvant chemotherapy in 126 operable breast cancers.
E Bélembaogo, V Feillel, P Chollet, H Curé, P Verrelle, F Kwiatkowski, J L Achard, G Le Bouëdec, J Chassagne, Y J Bignon. Eur J Cancer 1992

Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.
Y Remvikos, P Beuzeboc, A Zajdela, N Voillemot, H Magdelénat, P Pouillart. J Natl Cancer Inst 1989

Primary medical (neo-adjuvant) chemotherapy for operable breast cancer.
I E Smith, A L Jones, M E O'Brien, J A McKinna, N Sacks, M Baum. Eur J Cancer 1993

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Ann Brown, Roy Smith, Eleftherios P Mamounas, Bernard Fisher, Richard Margolese, Heather Theoret, Atilla Soran, D Lawrence Wickerham,[...]. J Clin Oncol 2003

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.
Gary H Lyman, Armando E Giuliano, Mark R Somerfield, Al B Benson, Diane C Bodurka, Harold J Burstein, Alistair J Cochran, Hiram S Cody, Stephen B Edge, Sharon Galper,[...]. J Clin Oncol 2005

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012

Preoperative chemotherapy for women with operable breast cancer.
J S D Mieog, J A van der Hage, C J H van de Velde. Cochrane Database Syst Rev 2007

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser,[...]. Lancet 2010

Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers.
G Calais, P Descamps, S Chapet, V Turgeon, A Reynaud-Bougnoux, E Lemarié, A Fignon, G Body, P Bougnoux, J Lansac. Int J Radiat Oncol Biol Phys 1993

The free transverse rectus abdominis musculocutaneous flap for breast reconstruction: one center's experience with 211 consecutive cases.
M A Schusterman, S S Kroll, M J Miller, G P Reece, B J Baldwin, G L Robb, C S Altmyer, F C Ames, S E Singletary, M I Ross. Ann Plast Surg 1994

Conservation surgery after primary chemotherapy in large carcinomas of the breast.
U Veronesi, G Bonadonna, S Zurrida, V Galimberti, M Greco, C Brambilla, A Luini, S Andreola, F Rilke, R Raselli. Ann Surg 1995

p53 protein overexpression and chemosensitivity in breast cancer. Institut Gustave-Roussy Breast Cancer Group.
M C Mathieu, S Koscielny, M L Le Bihan, M Spielmann, R Arriagada. Lancet 1995

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
T Aas, A L Børresen, S Geisler, B Smith-Sørensen, H Johnsen, J E Varhaug, L A Akslen, P E Lønning. Nat Med 1996

Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.
S Chevillard, J Lebeau, P Pouillart, C de Toma, C Beldjord, B Asselain, J Klijanienko, A Fourquet, H Magdelénat, P Vielh. Clin Cancer Res 1997

Endocrine therapy for advanced breast cancer: a review.
H B Muss. Breast Cancer Res Treat 1992

Lymphatic mapping and sentinel node biopsy in the patient with breast cancer.
J J Albertini, G H Lyman, C Cox, T Yeatman, L Balducci, N Ku, S Shivers, C Berman, K Wells, D Rapaport,[...]. JAMA 1996

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.